Anaheim, CA - Ranolazine, a partial inhibitor of fatty-acid oxidation, may represent the first new class of antianginal drug in over 20 years, according to Dr Bernard Chaitman (St Louis University, St ...

For patients undergoing elective percutaneous coronary intervention (PCI), pretreatment with the antianginal agent ranolazine substantially reduces the risk of periprocedural myocardial infarction (MI ...

Despite appropriate use criteria advocating the importance of trying 2 or more antianginal drugs prior to invasive treatment of coronary artery disease (CAD), up to one-third of patients undergoing ...

Anaheim, CA - Nicorandil, a potassium channel activator used for the treatment of chronic stable angina, may reduce the risk of major coronary events in angina patients, according to results from the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window After successful ...

On Medindia find the complete list of Antianginal And Antihypertensive drugs with their available forms and strength. More information is available on each drug including their price list. We ...

Please provide your email address to receive an email when new articles are posted on . In patients who underwent PCI, trimetazidine, a drug to improve myocardial metabolism, did not improve angina ...

Results of a UK study in this week¡¦s issue of THE LANCET suggest that the antianginal drug nicorandil could reduce the risk of cardiovascular disease associated with angina. Angina occurs in 10% of ...

Other classes of antianginal drugs that neither lower heart rate nor produce coronary vasodilatation have been developed. Among these drugs, the most recently approved for treatment of angina pectoris ...

Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...

Oral nicorandil, an antianginal drug, may decrease the risk of cardiac death and improve survival of hemodialysis (HD) patients after coronary revascularization, according to researchers. Masato ...